Not intended for diagnosis, treatment, or prevention of any condition
Doping control analysis of TB-500, a synthetic version of an active region of thymosin [PMID: 23084823] Laboratory literature summary: Doping control analysis of TB-500, a synthetic version of an active region of thymosin , in equine urine and plasma by liquid
Concomitant medicines : Clinicians should review all concurrent medications, particularly insulin or sulfonylureas, given the potential for hypoglycaemia with incretin-based agents
That is why the schedule section below is deliberately boring steadiness is the point
METAOD003: A Phase IIa (double-blind, placebo-controlled 4 4 Latin Square design) safety study with single doses (9, 27 and 54 mg AOD9604) administered orally (capsules) to 17 healthy, clinically obese males presenting with a BMI 35 kg/m 2